U.S. flag

An official website of the United States government

NM_000249.4(MLH1):c.188A>T (p.Asp63Val) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic/Likely pathogenic (2 submissions)
Last evaluated:
Dec 9, 2022
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001805680.6

Allele description [Variation Report for NM_000249.4(MLH1):c.188A>T (p.Asp63Val)]

NM_000249.4(MLH1):c.188A>T (p.Asp63Val)

Gene:
MLH1:mutL homolog 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
3p22.2
Genomic location:
Preferred name:
NM_000249.4(MLH1):c.188A>T (p.Asp63Val)
HGVS:
  • NC_000003.12:g.36996690A>T
  • NG_007109.2:g.8341A>T
  • NG_008418.1:g.1615T>A
  • NM_000249.4:c.188A>TMANE SELECT
  • NM_001167617.3:c.-102A>T
  • NM_001167618.3:c.-536A>T
  • NM_001167619.3:c.-444A>T
  • NM_001258271.2:c.188A>T
  • NM_001258273.2:c.-517+3027A>T
  • NM_001258274.3:c.-681A>T
  • NM_001354615.2:c.-439A>T
  • NM_001354616.2:c.-444A>T
  • NM_001354617.2:c.-536A>T
  • NM_001354618.2:c.-536A>T
  • NM_001354619.2:c.-536A>T
  • NM_001354620.2:c.-102A>T
  • NM_001354621.2:c.-629A>T
  • NM_001354622.2:c.-742A>T
  • NM_001354623.2:c.-723+2800A>T
  • NM_001354624.2:c.-639A>T
  • NM_001354625.2:c.-542A>T
  • NM_001354626.2:c.-639A>T
  • NM_001354627.2:c.-639A>T
  • NM_001354628.2:c.188A>T
  • NM_001354629.2:c.188A>T
  • NM_001354630.2:c.188A>T
  • NP_000240.1:p.Asp63Val
  • NP_001245200.1:p.Asp63Val
  • NP_001341557.1:p.Asp63Val
  • NP_001341558.1:p.Asp63Val
  • NP_001341559.1:p.Asp63Val
  • LRG_216t1:c.188A>T
  • LRG_216:g.8341A>T
  • NC_000003.11:g.37038181A>T
  • NM_000249.3:c.188A>T
Protein change:
D63V
Links:
dbSNP: rs1064795693
NCBI 1000 Genomes Browser:
rs1064795693
Molecular consequence:
  • NM_001167617.3:c.-102A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001167618.3:c.-536A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001167619.3:c.-444A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001258274.3:c.-681A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354615.2:c.-439A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354616.2:c.-444A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354617.2:c.-536A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354618.2:c.-536A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354619.2:c.-536A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354620.2:c.-102A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354621.2:c.-629A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354622.2:c.-742A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354624.2:c.-639A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354625.2:c.-542A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354626.2:c.-639A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001354627.2:c.-639A>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001258273.2:c.-517+3027A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001354623.2:c.-723+2800A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000249.4:c.188A>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258271.2:c.188A>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354628.2:c.188A>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354629.2:c.188A>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354630.2:c.188A>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV002053718Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)		Likely pathogenic
(Dec 9, 2022) 		germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

SCV002722481Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Pathogenic
(Jul 26, 2022) 		germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Fatal knowledge? Prenatal diagnosis and sex selection.

Wertz DC, Fletcher JC.

Hastings Cent Rep. 1989 May-Jun;19(3):21-7.

PubMed [citation]
PMID:
2722481

Prevalence and spectrum of DNA mismatch repair gene variation in the general Chinese population.

Zhang L, Qin Z, Huang T, Tam B, Ruan Y, Guo M, Wu X, Li J, Zhao B, Chian JS, Wang X, Wang L, Wang SM.

J Med Genet. 2022 Jul;59(7):652-661. doi: 10.1136/jmedgenet-2021-107886. Epub 2021 Jun 25.

PubMed [citation]
PMID:
34172528
PMCID:
PMC9252855
See all PubMed Citations (5)

Details of each submission

From Color Diagnostics, LLC DBA Color Health, SCV002053718.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

This missense variant replaces aspartic acid with valine at codon 63 in the ATP binding domain of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with colorectal cancer that demonstrated loss of MLH1 and PMS2 proteins via immunohistochemistry analysis (PMID: 23733757; communication with an external laboratory, ClinVar SCV002722481.1), and in an individual affected with unspecified cancer (PMID: 34172528). Several different missense variants at this codon have been classified as pathogenic (ClinVar Variation ID: 89920, 89934, 422297, 957817), supporting that this position is important for protein function. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Ambry Genetics, SCV002722481.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

The p.D63V pathogenic mutation (also known as c.188A>T), located in coding exon 2 of the MLH1 gene, results from an A to T substitution at nucleotide position 188. The aspartic acid at codon 63 is replaced by valine, an amino acid with highly dissimilar properties. This variant was previously reported in a 35 year old male diagnosed with colorectal cancer whose tumor analysis showed microsatellite instability and loss of MLH1 and PMS2 protein by immunohistochemistry (Ward R.L. et al., J. Clin. Oncol. 2013 Jul; 31(20):2554-62). Crystal structural analysis shows that this amino acid residue directly interacts with ATP and is indicated to be part of the ATP binding motif (Ambry internal data). A pathogenic mutation at the same codon, p.D63N, has been reported in a Hungarian family satisfying Amsterdam I criteria for HNPCC/Lynch syndrome. In this family, p.D63N segregated with disease, being detected in the affected proband (CRC at 25y) and his affected father (CRC at 40y) and was absent from 7 cancer-free relatives (Papp J et al. World J. Gastroenterol. 2007 May; 13(19):2727-32). The p.D63N variant has also been identified in multiple individuals with tumors demonstrating loss of MLH1 and PMS2 by immunohistochemistry (Ambry internal data). Another amino acid change at the same codon, p.D63E, has been classified as pathogenic by multifactorial analysis, which integrates the following lines of evidence to produce a quantitative likelihood of pathogenicity: in silico prediction models, segregation with disease, tumor characteristics, mutation co-occurrence, and functional assay results (Thompson B. et al. Nat Genet. 2014 Feb;46(2):107-15; available at [www.insight-group.org/variants/classifications/]). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024